Published: 8 October 2026 | WHO publication: 7 October 2026
At a Glance
- WHO has launched a global roadmap for hypertensive disorders of pregnancy for 2026–2035 and beyond.
- Pre-eclampsia and eclampsia remain major causes of maternal death and severe morbidity.
- WHO reports hypertensive disorders account for about 16% of maternal deaths globally.
- The roadmap focuses on research and innovation, norms and standards, access to health products, implementation, and advocacy/accountability.
Why this matters
Pre-eclampsia can progress rapidly and may cause seizures, stroke, organ injury, fetal growth restriction, preterm birth, stillbirth and maternal or newborn death. Early detection, appropriate monitoring and timely treatment are therefore central to safe maternity care.
Key system priorities
- Reliable blood-pressure measurement during antenatal care.
- Appropriate testing and risk assessment.
- Timely access to essential medicines and referral care.
- Improved emergency obstetric capability.
- Stronger implementation of evidence-based protocols.
Clinical point
WHO notes that magnesium sulfate can reduce the risk of progression from pre-eclampsia to eclampsia substantially, yet access and correct use remain inconsistent in many settings. The roadmap is intended to close these implementation gaps.
India relevance
The roadmap is directly relevant to antenatal care, labour-room protocols, referral systems and maternal-death prevention programmes in India. State and national obstetric protocols should remain the operational reference for individual patient care.
Official Source
WHO — Global roadmap for hypertensive disorders of pregnancy, 2026–2035 and beyond
MedBodh note: This is a public-health and clinical-policy summary. Management of hypertension in pregnancy should follow current obstetric guidelines and urgent-care pathways.